Literature DB >> 2110815

The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.

A Keohane1, J Godden, I J Stratford, G E Adams.   

Abstract

We have investigated the cross-sensitivity of a number of cell lines to three different classes of bioreductive drugs under both aerobic and hypoxic conditions. The cell lines used were selected for their sensitivity to DNA-damaging agents and fall into two groups. One group, MMC cells derived from CHO-K1 cells (Robson et al., 1985), show a range of sensitivities to mitomycin C in air. The second group, irs cells were cloned from V79 Chinese hamster fibroblasts (Jones et al., 1987) and exhibit sensitivity to ionising radiation. The sensitivity of both groups of cells to mitomycin C (MMC), RSU-1069 and SR4233 was assessed under aerobic and hypoxic conditions. No difference in aerobic or hypoxic toxicity of MMC was observed for CHO-K1 or MMC sensitive cell lines (MMC-2 and MMC-3). However, the MMC-resistant cell line (MMCr) was 10 times more sensitive under hypoxic than aerobic conditions. This suggests that MMCr cells lack or are deficient in the enzymes responsible for activating MMC under aerobic conditions compared to other MMC cells. In contrast, differential toxicities of between 3 and 30 have been observed for all CHO cells treated with RSU-1069 and SR4233. Treatment of V79 and irs cells with RSU-1069 and SR4233 also resulted in selective toxicity towards hypoxic cells. Differential toxicities between 50 and 100 were observed for V79 cells. For both RSU-1069 and SR4233, the hypoxic toxicities were similar in V79 and irs cells but in air, the radiation sensitive cells were up to 10 times more sensitive than wild type cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110815      PMCID: PMC1971598          DOI: 10.1038/bjc.1990.162

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  The role of catalytic superoxide formation in the O2 inhibition of nitroreductase.

Authors:  R P Mason; J L Holtzman
Journal:  Biochem Biophys Res Commun       Date:  1975-12-15       Impact factor: 3.575

2.  Isolation and cross-sensitivity of X-ray-sensitive mutants of V79-4 hamster cells.

Authors:  N J Jones; R Cox; J Thacker
Journal:  Mutat Res       Date:  1987-05       Impact factor: 2.433

3.  Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins.

Authors:  M I Walton; C R Wolf; P Workman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-04       Impact factor: 7.038

4.  Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.

Authors:  S R Keyes; P M Fracasso; D C Heimbrook; S Rockwell; S G Sligar; A C Sartorelli
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

5.  SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.

Authors:  E M Zeman; J M Brown; M J Lemmon; V K Hirst; W W Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-07       Impact factor: 7.038

Review 6.  The hypoxic tumor cell: a target for selective cancer chemotherapy.

Authors:  K A Kennedy; B A Teicher; S Rockwell; A C Sartorelli
Journal:  Biochem Pharmacol       Date:  1980-01-01       Impact factor: 5.858

7.  Isolation and characterization of Chinese hamster ovary cell lines sensitive to mitomycin C and bleomycin.

Authors:  C N Robson; A L Harris; I D Hickson
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

8.  Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H: (quinone-acceptor)oxidoreductase.

Authors:  J J Schlager; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions.

Authors:  I J Stratford; P O'Neill; P W Sheldon; A R Silver; J M Walling; G E Adams
Journal:  Biochem Pharmacol       Date:  1986-01-01       Impact factor: 5.858

10.  RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo.

Authors:  G E Adams; I Ahmed; P W Sheldon; I J Stratford
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

View more
  7 in total

1.  Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs.

Authors:  Ryan G Snodgrass; Abby C Collier; Amy E Coon; Chris A Pritsos
Journal:  J Biol Chem       Date:  2010-04-23       Impact factor: 5.157

2.  Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.

Authors:  Daniele Grazziotin Soares; Alexandre E Escargueil; Virginie Poindessous; Alain Sarasin; Aimery de Gramont; Diego Bonatto; João Antonio Pêgas Henriques; Annette K Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-26       Impact factor: 11.205

3.  Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.

Authors:  A V Patterson; M P Saunders; E C Chinje; D C Talbot; A L Harris; I J Strafford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures.

Authors:  K A Biedermann; J Wang; R P Graham; J M Brown
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

5.  Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.

Authors:  K H Wong; C J Koch; C A Wallen; K T Wheeler
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

Review 6.  SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.

Authors:  J M Brown
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

7.  Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

Authors:  A V Patterson; H M Barham; E C Chinje; G E Adams; A L Harris; I J Stratford
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.